CUE BIOPHARMA INC (CUE)
US22978P1066 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 14.94M 374.29% | 1.25M -91.63% | 5.49M 339.20% | 9.504M 73.11% | 10.551M 11.02% | 19.209M 82.06% | 16.966M -11.68% | 39.198M 131.04% | 19.534M -50.17% | 55.708M 185.18% | 113.69M 104.08% | |
| EBITDA YoY % growth | -42.45M 3.48% | -52.58M -23.86% | -51.436M 2.18% | -58.702M -14.13% | -54.322M 7.46% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -43.71M 2.95% | -53.5M -22.40% | -51.992M 2.82% | -42.419M 18.41% | -41.211M 2.85% | -39.879M 3.23% | -51.799M -29.89% | -45.087M 12.96% | -74.481M -65.19% | -50.285M 32.49% | -7.533M 85.02% | |
| Operating Margin | -292.57% | -4,280.00% | -947.03% | -446.33% | -390.59% | -207.60% | -305.31% | -115.02% | -381.29% | -90.26% | -6.63% | |
| EPS YoY % growth | -1.40 10.26% | -1.50 -7.14% | -1.11 26.00% | -0.77 30.66% | -0.56 27.82% | -0.47 15.91% | -0.49 -5.95% | -0.48 2.04% | -0.49 -2.08% | -0.46 6.12% | -0.47 -2.17% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.16 45.67% | -0.15 39.40% | -0.13 32.67% | -0.13 20.79% | -0.14 12.39% |
| Revenue Q2Q % growth | 1.596M -12.36% | 1.28M -25.45% | 1.616M -39.20% | 1.65M -50.54% | 1.717M 7.58% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -10.188M 25.50% | -20.614M -62.73% | -10.203M 1.74% | -10.129M -13.65% | -10.371M -1.80% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.17 29.17% | -0.19 | 0.02 | 12.56% |
| Q2 2024 Q2Q % growth | -0.20 31.03% | -0.29 | 0.09 | 30.27% |
| Q1 2024 Q2Q % growth | -0.25 13.79% | -0.28 | 0.03 | 12.23% |
| Q4 2023 Q2Q % growth | -0.29 23.68% | -0.28 | -0.01 | -3.28% |
| Q3 2023 Q2Q % growth | -0.24 22.58% | -0.35 | 0.11 | 30.62% |
| Q2 2023 Q2Q % growth | -0.29 21.62% | -0.31 | 0.02 | 5.86% |
| Q1 2023 Q2Q % growth | -0.29 34.09% | -0.29 | 0.00 | 0.99% |
| Q4 2022 Q2Q % growth | -0.38 -52.00% | -0.31 | -0.07 | -21.37% |
| Q3 2022 Q2Q % growth | -0.31 24.39% | -0.38 | 0.07 | 19.23% |
| Q2 2022 Q2Q % growth | -0.37 -12.12% | -0.43 | 0.06 | 13.46% |
| Q1 2022 Q2Q % growth | -0.44 -7.32% | -0.43 | -0.01 | -1.90% |
| Q4 2021 Q2Q % growth | -0.25 30.56% | -0.39 | 0.14 | 35.71% |
| Q3 2021 Q2Q % growth | -0.41 -20.59% | -0.39 | -0.02 | -4.09% |
| Q2 2021 Q2Q % growth | -0.33 13.16% | -0.42 | 0.09 | 21.46% |
| Q1 2021 Q2Q % growth | -0.41 14.58% | -0.38 | -0.03 | -7.39% |
| Q4 2020 Q2Q % growth | -0.36 | -0.35 | -0.01 | -1.84% |
| Q3 2020 Q2Q % growth | -0.34 -9.68% | -0.39 | 0.05 | 12.33% |
| Q2 2020 Q2Q % growth | -0.38 17.39% | -0.43 | 0.05 | 11.68% |
| Q1 2020 Q2Q % growth | -0.48 11.11% | -0.35 | -0.13 | -35.79% |
| Q4 2019 Q2Q % growth | -0.36 | -0.45 | 0.09 | 20.35% |
| Q3 2019 Q2Q % growth | -0.31 | -0.44 | 0.13 | 30.24% |
| Q2 2019 Q2Q % growth | -0.46 | -0.57 | 0.11 | 18.67% |
| Q1 2019 Q2Q % growth | -0.54 | -0.40 | -0.14 | -33.66% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 3.336M 58.86% | 1.535M | 1.801M | 117.33% |
| Q2 2024 Q2Q % growth | 2.658M 92.33% | 1.302M | 1.356M | 104.15% |
| Q1 2024 Q2Q % growth | 1.717M 818.18% | 1.225M | 492K | 40.16% |
| Q4 2023 Q2Q % growth | 1.821M 1,114.00% | 1.583M | 238K | 15.03% |
| Q3 2023 Q2Q % growth | 2.1M 2,900.00% | 1.144M | 956K | 83.57% |
| Q2 2023 Q2Q % growth | 1.382M 4,506.67% | 916.575K | 465.425K | 50.78% |
| Q1 2023 Q2Q % growth | 187K -81.30% | 1.97M | -1.783M | -90.51% |
| Q4 2022 Q2Q % growth | 150K -98.18% | 104.788K | 45.213K | 43.15% |
| Q3 2022 Q2Q % growth | 70K -97.08% | 444.733K | -374.733K | -84.26% |
| Q2 2022 Q2Q % growth | 30K -98.91% | 1.143M | -1.113M | -97.38% |
| Q1 2022 Q2Q % growth | 1M -35.48% | 3.085M | -2.085M | -67.59% |
| Q4 2021 Q2Q % growth | 8.25M 1,618.75% | 2.996M | 5.254M | 175.37% |
| Q3 2021 Q2Q % growth | 2.4M 242.86% | 1.884M | 516K | 27.39% |
| Q2 2021 Q2Q % growth | 2.74M 153.70% | 1.068M | 1.672M | 156.55% |
| Q1 2021 Q2Q % growth | 1.55M 72.22% | 591.456K | 958.544K | 162.07% |
| Q4 2020 Q2Q % growth | 480K -54.29% | 1.346M | -866K | -64.34% |
| Q3 2020 Q2Q % growth | 700K -28.57% | 1.712M | -1.012M | -59.11% |
| Q2 2020 Q2Q % growth | 1.08M 1.89% | 2.108M | -1.028M | -48.77% |
| Q1 2020 Q2Q % growth | 900K 143.24% | 1.852M | -952K | -51.40% |
| Q4 2019 Q2Q % growth | 1.05M | 881.73K | 168.27K | 19.08% |
| Q3 2019 Q2Q % growth | 980K | 404K | 576K | 142.57% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 57.84% | 0% | 8.56% |
| Revenue | 0% | 58.02% | -15.71% | -15.51% |